Balyasny Asset Management
LAB icon

Balyasny Asset Management’s Standard BioTools LAB Stock Holding History

Balyasny Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7K Buy
+38,535
New +$36.4K ﹤0.01% 2919
2025
Q4 		– Sell
-86,005
Closed -$112K – 3342
2025
Q3 		$112K Hold
86,005
– – ﹤0.01% 2780
2025
Q2 		$103K Hold
86,005
– – ﹤0.01% 2686
2025
Q1 		$92.9K Sell
86,005
-648,999
-88% -$911K ﹤0.01% 2688
2024
Q4 		$1.29M Sell
735,004
-256,700
-26% -$478K ﹤0.01% 1846
2024
Q3 		$1.91M Sell
991,704
-6,458
-0.6% -$12.6K ﹤0.01% 1686
2024
Q2 		$1.77M Sell
998,162
-3,846,889
-79% -$9.4M ﹤0.01% 1578
2024
Q1 		$13.1M Buy
4,845,051
+2,662,864
+122% +$6.43M 0.02% 813
2023
Q4 		$4.82M Sell
2,182,187
-514,523
-19% -$1.1M 0.01% 1124
2023
Q3 		$7.82M Buy
2,696,710
+595,020
+28% +$1.56M 0.02% 935
2023
Q2 		$4.06M Buy
+2,101,690
New +$4.15M 0.01% 1133
2022
Q3 		– Sell
-1,137,361
Closed -$1.82M – 3065
2022
Q2 		$1.82M Buy
+1,137,361
New +$2.81M 0.01% 1468
2022
Q1 		– Sell
-700,000
Closed -$2.74M – 2666
2021
Q4 		$2.74M Buy
700,000
+381,009
+119% +$1.78M 0.01% 1090
2021
Q3 		$2.1M Buy
+318,991
New +$2.1M 0.01% 1112
2018
Q2 		– Sell
-25,488
Closed -$149K – 1982
2018
Q1 		$149K Buy
25,488
+14,388
+130% +$94.5K ﹤0.01% 1798
2017
Q4 		$65K Buy
+11,100
New +$60.8K ﹤0.01% 2000

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Balyasny Asset Management's LAB Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Standard BioTools (LAB) in Q2 2026: 38,535 shares worth $31.7K. The stake represents ﹤0.01% of the portfolio and ranks #2919 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in LAB as recently as Q3 2025.

Balyasny Asset Management first reported a position in LAB in Q4 2017 and has held it in 16 quarters since. The position peaked at $13.1M in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Balyasny Asset Management held 38,535 shares of Standard BioTools worth $31.7K as of Q2 2026.
  • Standard BioTools was a new Balyasny Asset Management position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2919 holding.
  • Balyasny Asset Management first reported a position in Standard BioTools in Q4 2017 and has held it in 16 quarters since.
  • Balyasny Asset Management's Standard BioTools position peaked at $13.1M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.